2010 News Releases

2010 News Releases

Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
12/13/10GTx Presents Results of the Capesaris(TM) (GTx-758) Phase II Proof of Concept Pharmacokinetic-Pharmacodynamic Clinical TrialPrinter Friendly Version
11/15/10GTx Presents Preclinical Studies of GTx-758, a Selective Estrogen Receptor Alpha Agonist for First Line Treatment of Advanced Prostate Cancer, and GTx-230, an Orally Available Tubulin Antagonist for Cancer Refractory to Taxane and Vinca Alkaloid TherapyPrinter Friendly Version
11/11/10GTx Announces Corporate Presentation at the Lazard Capital Markets Annual Healthcare ConferencePrinter Friendly Version
11/09/10GTx, Inc. Reports Third Quarter 2010 Corporate ResultsPrinter Friendly Version
11/08/10GTx Appoints Dr. Barry Furr to the Board of DirectorsPrinter Friendly Version
11/03/10GTx Awarded $1.2 Million in Grants for Qualifying Therapeutic Discovery ProjectsPrinter Friendly Version
11/02/10GTx, Inc. Announces Third Quarter 2010 Financial Results Conference Call and WebcastPrinter Friendly Version
10/27/10GTx Announces Pricing of Public Offering of Common StockPrinter Friendly Version
10/26/10GTx Announces Proposed Public Offering of Common StockPrinter Friendly Version
09/16/10GTx Announces Corporate Presentation at the UBS Global Life Sciences ConferencePrinter Friendly Version
09/15/10GTx Announces That GTx-758, a Novel Oral Selective Estrogen Receptor Alpha Agonist Being Developed to Treat Advanced Prostate Cancer, Induced Medical Castration in a Phase II PK/PD Clinical TrialPrinter Friendly Version
08/09/10GTx, Inc. Reports Second Quarter 2010 Corporate ResultsPrinter Friendly Version
07/26/10GTx, Inc. Announces Second Quarter 2010 Financial Results Conference Call and WebcastPrinter Friendly Version
06/21/10GTx Announces Ostarine Increased Lean Body Mass and Leg Press Strength in Head to Head Clinical StudyPrinter Friendly Version
06/08/10GTx Announces Toremifene 80 mg Treatment Demonstrated Improved Fracture Reduction and Safety Profile in Men With Prostate Cancer on ADT Younger Than Age 80Printer Friendly Version
06/07/10GTx Presents Additional Study Results in Quality of Life Improvements from the Phase IIb Clinical Trial Evaluating Ostarine(TM) for Cancer Induced Muscle WastingPrinter Friendly Version
06/02/10GTx Announces Corporate Presentation at Jefferies 2010 Global Life Sciences ConferencePrinter Friendly Version
05/27/10GTx Announces Upcoming AUA Presentation of Additional Study Results from the Phase III Clinical Trial Evaluating Toremifene 80 mg for the Reduction of Fractures in Men with Prostate Cancer on ADTPrinter Friendly Version
05/25/10GTx Announces Top Line Results of Phase III Clinical Trial Evaluating Toremifene 20 mg for the Prevention of Prostate Cancer in Men with High Grade PINPrinter Friendly Version
05/20/10GTx Announces Upcoming ASCO Presentations of Additional Study Results from Clinical Trials Evaluating Ostarine(TM) for Cancer Cachexia and Toremifene 80 mg for the Reduction of Fractures in Men with Prostate Cancer on ADTPrinter Friendly Version
05/20/10GTx Announces Corporate Presentation at Citi Global Health Care ConferencePrinter Friendly Version
05/04/10GTx, Inc. Reports First Quarter 2010 Corporate ResultsPrinter Friendly Version
04/28/10GTx, Inc. Announces First Quarter 2010 Financial Results Conference Call and WebcastPrinter Friendly Version
03/23/10GTx and Ipsen Expand PartnershipPrinter Friendly Version
03/15/10GTx Provides Corporate Update and Reports 2009 Financial ResultsPrinter Friendly Version
03/02/10GTx, Inc. Announces Fourth Quarter and Year End 2009 Financial Results Conference Call and WebcastPrinter Friendly Version
Print Page E-mail Page RSS Feeds E-mail Alerts Financial Tear Sheet